Physician profile
Stanley J Conhon
NPI 1487642575
$10,013.20
in general payments reported to CMS, 2019-2025
48 companies · $676 in 2025
The $676 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,708 · 2020: $442 · 2021: $771 · 2022: $2,030 · 2023: $1,797 · 2024: $2,589 · 2025: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,062.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,811.82 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,772.08 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $972.45 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $677.34 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $589.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $336.24 | 2019-2024 | Jardiance, Stiolto Respimat |
| Pfizer INC. | $309.18 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $245.01 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $225.82 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $215.44 | 2021-2024 | |
| Lilly USA, LLC | $191.35 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Supernus Pharmaceuticals, INC. | $189.76 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $176.74 | 2022-2024 | Rexulti, Abilify Mycite |
| Astellas Pharma US INC | $154.49 | 2019-2025 | Veozah |
| Sunovion Pharmaceuticals INC. | $146.04 | 2019-2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Conhon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.